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Abstract
Background: Suboptimal medication adherence is a significant threat to public health and resources. Devices that
organise weekly doses by time and day are commonly used to reduce unintentional non-adherence. However,
there is limited evidence to support their use. This systematic review was conducted to evaluate current evidence
for their efficacy, safety and costs.
Methods: A pre-defined search of electronic databases from inception to January 2013 augmented with
hand-searching was conducted. No limits were placed on publication date. Studies that compared organisation
devices used by patients administering their own medication with standard medication packaging regardless of
study design were eligible for inclusion. Studies that solely explored dispensing aspects of organisation devices
were included whether or not they compared this to standard care. Screening of articles for inclusion and data
extraction were completed independently by two reviewers with disagreements resolved by discussion. Outcomes
were categorised into impact on health, medication adherence, healthcare utilisation, dispensing errors, supply
procedures and costs. Risk of bias was also assessed.
Results: Seventeen studies met the inclusion criteria. Health outcomes were investigated in seven studies of which
three reported a positive effect associated with organisation devices. Medication adherence was reported in eight
studies of which three reported a positive effect. Three studies reported health care utilisation data but overall
results are inconclusive. No optimal dispensing or supply procedures were identified. Economic assessment of the
impact of organisation devices is lacking. All studies were subject to a high risk of bias.
Conclusions: Evidence regarding the effects of medication organisation devices was limited, and the available
evidence was susceptible to a high risk of bias. Organisation devices may help unintentional medication
non-adherence and could improve health outcomes. There is a strong need for more studies that explore the
impact of such devices on patients, and an equally pressing need for studies that explore the impacts on
healthcare services.
Trial registration: This systematic review is registered with PROSPERO (Registration number CRD42011001718).
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Background
An estimated 25 % to 50 % of all patients diagnosed with
a chronic disease do not take their medication as pre-
scribed [1, 2]. Some of this non-adherence to medication
is intentional, with patients actively choosing to deviate
from their prescribed regimen because of their beliefs
about their illness and medicines, and their experiences
of treatment [3]. However patients frequently cite factors
such as forgetting, being too busy, or experiencing a
change in their daily routines as the main reasons for
their non-adherence [4]. Thus, a significant amount of
non-adherence is likely to be unintentional.
Non-adherence to medication poses a significant risk
to public health, and is an important issue for policy
makers. Non-adherence has been demonstrated to result
in poorer health outcomes [5] and is associated with an
increase in hospital admissions estimated to cost the UK
National Health Service up to £196 million per year [6]
and the US $100 billion [7]. Thus simple cost-effective
interventions to reduce non-adherence are sought to im-
prove public health and reduce avoidable expenditure in
healthcare systems.
One such intervention is a Medication Organisation
Device (MOD). There are a wide variety of MODs avail-
able but all are based on the same principle; at their sim-
plest they comprise a plastic tray formed of a series of
wells often in 7 x 4 format providing 28 consecutive com-
bined doses for a one week period. They are designed to
help patients prescribed multiple medicines to remember
which of these need to be taken at the different times of
day, and facilitate identification of any missed doses [8].
The underlying assumption is that MODs are an aide
memoire and reduce the burden of complex medication
regimens. MODs can also be associated with additional
features such as electronic reminder systems which are
usually light or sound. Whilst these features may be bene-
ficial, the aim of this review was to report the effects of
MODs, not reminder systems.
Despite the wide use of MODs [9] there is limited evi-
dence for their use or guidance on how, when, or by
whom they should be used [10]. Previous reviews of the
evidence have focussed on the impact of MODs on ad-
herence and health outcomes [10–13], and whilst this is
the principal purpose of MODs, there are other potential
benefits and disadvantages that are overlooked by focus-
sing on these two outcomes alone.
If MODs successfully increase adherence and improve
health outcomes, then it should be expected that they
could also be associated with a reduction in the need for
more expensive healthcare interventions such as visits to
the family doctor or a reduction in hospital and nursing
home admissions [5, 14]. Thus the potential economic
benefits and wider healthcare implications of MODs
should be explored.
As well as the potential benefits, MODs may also
introduce risks. Foremost they introduce an additional
step in the dispensing process when the pharmacist, pa-
tient or carer transfers prescribed medications into the
MOD. Thus it is important to review evidence of the ef-
fect of MODs on dispensing errors. There are also finan-
cial and opportunity costs to healthcare systems
incurred by dispensing MODs, such as the acquisition
cost of the MOD and the time to fill the MOD. Thus,
when considering the utility of MODs compared to
usual care, it is important to consider cost effectiveness
as well as clinical effectiveness.
The aim of this systematic review was to identify
current evidence for simple MODs in any population
and for any study design with respect to the following
outcomes;
1. Patient health outcomes and quality of life.
2. Patient adherence to medication.
3. Patient healthcare and social services utilisation.
4. Pharmacy dispensing errors.
5. Pharmacy supply procedures and associated costs.
Methods
This systematic review was conducted in accordance
with PRISMA and Cochrane guidelines [15, 16] and the
study protocol registered with PROSPERO (Registration
number CRD42011001718).
Empirical studies of any design, on the use of MODs
were included if they reported any of the following:
 Adherence to medicines (using an objective measure
(e.g. pill count or electronic monitoring);
 Health outcomes;
 Health related quality of life;
 Health or social care utilisation;
 Dispensing or administration errors;
 Costs associated with prescribing or medicine
supply.
We focus on pill counts and electronic monitoring
because these are the gold standard measures of
medication adherence, avoid self-reporting bias, and
unlike other methods of adherence measurement pro-
vide a quantifiable estimate of the magnitude of non-
adherence [17].
Studies were excluded if: the intervention incorporated
additional reminder systems such as alarms, telephone/
SMS messaging, daily medication reminder ‘tick’ charts;
there was direct observation of medicine administration
by a health care professional; medication was not self-
administered; the MOD was used as part of a complex
intervention where the independent effect of the MOD
on outcomes could not be isolated; the study was not
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reported in English. There were no limits placed on date
of publication.
Search strategies and information sources
The following electronic databases were searched from incep-
tion to January 2013: The library of the Cochrane collabor-
ation (http://www.cochranelibrary.com/cochrane-database-
of-systematic-reviews/), MEDLINE, PsycINFO, AMED,
CINAHL, trials listed as complete in Current Controlled Tri-
als (http://controlled-trials.com/) and York Centre for Review
and Dissemination databases (http://www.crd.york.ac.uk/
crdweb/SearchPage.asp). Thirty different terms referring to
adherence, health outcomes, quality of life, health and social
care utilisation, errors and costs were combined with 27 refer-
ring to drug packaging and drug delivery systems including
MOD-specific trade names. Searches were limited to ‘human’
(Fig. 1). The same terms were utilised for each database but
with appropriate translation of database specific syntax, for
example the symbols and wording required to account for
truncation, multiple accepted spellings, adjacency and Bool-
ean operators. The following additional searches were under-
taken: hand searching of the reference lists of all identified
review articles (including the reference lists of foreign lan-
guage review articles), of articles whether or not the paper was
ultimately included; personal communication with packaging
companies and keyword searches in the Google Scholar
search engine (http://scholar.google.com).
Study selection
The titles and abstracts of all articles were reviewed in-
dependently against inclusion criteria by two of four re-
viewers (CA, LC, EP, TB). Disagreement was resolved
by discussion. Full texts of potentially relevant papers
(n = 272) were independently screened by two of three
reviewers (CA, EP, TB) using a data extraction tool (see
below). When agreement could not be reached, a third
reviewer moderated the final decision [16].
Data extraction
An electronic data extraction form was developed in
Excel and piloted to ensure consistency of data extrac-
tion across researchers. The form included fields for in-
formation about the paper (e.g. authors, year and place
of publication); participants and setting of the study (e.g.
country, sample size, age range, ethnicity); key study de-
tails (e.g. description of methods, study design, setting of
research, delivery methods and sampling techniques;
intervention and comparator details; outcomes and how
they were measured, information to assess risk of study
bias, and a summary of results, including summary sta-
tistics for meta-analyses. Where possible MODs were
described according to seal type (unsealed (reusable)) or
sealed (heat- or cold-sealed single-use) and configuration
of wells.
Data for all included studies were independently ex-
tracted by two reviewers (EP and SW) and any differ-
ences were resolved by discussion. For studies with
missing data or ambiguities, the corresponding author
was contacted for clarification.
Assessing risk of bias in individual studies
Two reviewers (SW, EP) independently assessed in-
cluded studies using the Cochrane risk of bias tool [16].
Consensus on the final risk classifications was reached
through discussion. Where the study design did not per-
mit randomisation or blinding of assessors this was
noted as such designs are at greater risk of bias.
Data analysis
A priori, a meta-analysis was planned, but due to hetero-
geneity in the identified studies was not undertaken. Re-
sults were tabulated and reported according to the pre-
defined outcomes.
Results
Study selection
The searches identified 8122 potential studies. After re-
moval of duplicates and screening of titles, abstracts and
full papers against the inclusion criteria, 17 studies were
included. Figure 2 summarises the details of the selec-
tion process and reasons for exclusion.
Overview of studies
A summary of the 17 included studies is shown in
Table 1. They were mostly undertaken in either the USA
or UK. Ten (59 %) were Randomised Controlled Trials
(RCTs), two were prospective cohort studies, two were
cross sectional, and one used multiple methods. This
final study utilised questionnaires (to collect health out-
come and healthcare utilisation) and, a combination of
direct observation and audit of pharmacy log books (to
collect data on dispensing errors, supply procedures and
costs) [18]. Two studies were audits. Nine of the 17
studies were published between 1980 and 1999, and a
further eight between 2000 and 2009. No studies mea-
sured the impact of MODs on quality of life or social
service utilization. No studies declared any conflict of
interest.
For the studies reporting age, all participants were
adults and the median (interquartile) age across these
studies was 58.0 (51.5, 78.4) years. Eight studies included
participants prescribed medication for the treatment of a
chronic condition, and three studies included patients
prescribed an antihypertensive. The majority of the stud-
ies were in domiciliary settings (n = 13). One study [19]
examined the effect of MODs on dispensing procedures
and no patient data were reported.
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Five of the seventeen studies provided little or no infor-
mation on the type of MOD assessed. Where the type of
MOD was specified similar proportions used sealed and un-
sealed devices. Similar wide variation was demonstrated in
terms of comparator (where applicable) and method of fill.
Risk of bias
Table 2 summarises the risk of bias in included studies.
Only three of the nine RCTs reported randomisation
details, and none reported blinding of researchers or
treatment providers. Other risks of bias identified but
Fig. 1 Search terms and syntax for Ovid EmBase (adjusted for other databases)
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not specified in the tool included baseline differences
between groups not being accounted for in analyses
[18, 20], and minimal information on participants [21, 22]
or analytical procedures [21].
Effect of MODs
The following sections report the clinical and cost
effects of MODs; none of the included studies
reported cost-effectiveness.
Health outcomes
Table 3 summarises the impact of MODs on health out-
comes for seven studies from six papers (including five
RCTs) [18, 20, 23–26]. Three RCTs measured changes in
blood pressure [20, 25, 26]. The study of patients with
diabetes [26] reported a significant reduction in diastolic
blood pressure and HbA1c for the MOD group com-
pared to standard care. In contrast Becker et al. reported
no change in diastolic blood pressure, after controlling
for baseline/pre-enrolment values and age [20], and
Rehder et al. [25] reported no change in systolic blood
pressure in the MOD group.
A prospective longitudinal study of patients prescribed
medication for HIV reported a significant improvement
in health outcome (reduced viral load) [24] A cross-
sectional study of older people prescribed a range of
medication in a MOD [18] reported fewer adverse drug
reactions when pharmacist-filled MODs were used com-
pared with either MODs filled by the patient, carer/fam-
ily member, or community nurse, or medication
Fig. 2 Flow diagram of articles included in the review
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Table 1 Summary of included studies
First Author Year Design Location Condition Setting Age
(mean,
(range))
Type of MOD (format) Comparator MOD filled
by
Total
n
Becker [20] 1986 RCT USA Hypertension Hospital
Outpatient
nr Sealed. 28 consecutive-dose
foil backed blisters (7x4).
Packs were perforated so that
blisters could be detached.
Standard
packaging
(bottles)
Automatic
device
165
Carruthers [32] 2008 Audit Australia Mixed Care Home nr Sealed. 28 consecutive-dose
foil backed blisters (7x4).
Websterpaks
n/a Pharmacy nr *
Crome [27] 1982 RCT UK Mixed Hospital
Inpatient
80.29
(68-98)
Unsealed, 28 consecutive-
dose compartments (7x4).
Dosett®
Standard
packaging
(bottles)
Unclear 78
Feetam [21] 1982 Prospective UK Mental
Illness
Community 42.40
(18-68)
Unsealed, 28 consecutive-
dose compartments (7x4).
Can be divided into single
days for convenience.
Medidos®
Standard
packaging
(bottles)
Unclear 10
Huang [23] 2000 RCT USA Vitamin
supplements
in healthy
volunteers
Community 58.00
(nr)
Unsealed. Seven consecutive-
dose compartments (7x1).
Standard
packaging
(bottles)
Patient 183
Huang [23] 2000 RCT USA Vitamin
supplements
in healthy
volunteers
Community 65.00
(nr)
Unsealed. Seven consecutive-
dose compartments (7x1).
Standard
packaging
(bottles)
Patient 291
Levings [33] 1999 Audit Australia Mixed Community 78.00
(nr)
nr nr Various nr Ɨ
MacIntosh [28] 2007 RCT Canada Cancer Hospital
Outpatient
64.00
(42-81)
Unsealed. 14 consecutive-
dose compartments (7x2)
Standard
packaging
(nr)
Researcher 21
McElnay [19] 1992 Cross-
section
UK None Community nr Unsealed, 28 consecutive-
dose compartments, various
format: Medisystem® (7 of
4x1); Medidos® (7x4), Supercel
(7x4, pouches); Dosett®(7x4);
Pill Mill® (1x28, wheel-type);
Medi-wheel® (4 of 7x1,
stacked wheel-type).
n/a Pharmacist/
technician
6
Petersen [24] 2007 Prospective USA HIV Community 44.00
(38-49)
nr Standard
packaging
(bottles)
n/s 269
Rehder [25] 1980 RCT USA Hypertension Hospital
Outpatient
51.35
(31-69)
Unsealed, 28 consecutive-
dose compartments
Mediset®(7x4)
Standard
packaging
(bottles)
Pharmacy 50
Roberts [18] 2004 Multiple Australia Mixed Community 76.80 nr n/a Pharmacy 353
Ryan-Woolley
[29]
2005 RCT UK Mixed Care Home 78.80
(67-92)
unclear Standard
packaging
(nr)
Pharmacy 62
Simmons [26] 2000 RCT New
Zealand
Diabetes Community 54.06
(nr)
Sealed. 28 consecutive-dose
foil backed blisters (7x4).
Standard
packaging
(nr)
Pharmacy 68
Skaer [31] 1993 RCT USA Diabetes Pharmacy 51.74 Sealed Standard
packaging
(nr)
Pharmacy
or
researcher
131
Skaer [30] 1993 RCT USA Hypertension Pharmacy 56.49
(nr)
Sealed Standard
packaging
(nr)
Pharmacy
or
researcher
163
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supplied in standard packaging. However a limitation of
this comparison was that the patient groups differed in
functional ability as assessed by the Older Americans
Resource Scale for Instrumental Activities of Daily Liv-
ing (OARS-IADL) (mean scores were lower for the
group receiving MODs filled by pharmacists compared
with those filled by a non-pharmacist.
The remaining two studies, both RCTs [23], identified
no significant improvement in health outcomes for pa-
tients using self-filled MODs.
Medication adherence
Eight studies (seven RCTs and one prospective longitu-
dinal study, reported the effect of MODs on medication
adherence as summarised by Table 4. Adherence was es-
timated by pill count in all studies; the prospective study
used additional electronic monitoring for the control
group only [24]. Adherence exceeded 80 % for both the
intervention and control group in five of the eight stud-
ies. Three studies reported a significant improvement in
adherence [22, 24, 25] for the MOD group and three
studies failed to identify any difference between the two
groups [20, 23, 27]. One study [28] had very high rates
of adherence to an oral anticancer medication in both
the standard packaging and MOD group, with 18 of the
21 patients in the first group and 17 of the 21 in the lat-
ter group having 100 % adherence. The non-randomised
study [24] used marginal structural models to estimate
the mean difference in percentage of doses taken be-
tween patients receiving a MOD and those using stand-
ard medication packaging and this identified a 4 %
increase in adherence in participants using MODs.
Table 1 Summary of included studies (Continued)
Stewart [34] 2001 Cross-
section
UK Mixed Community nr nr n/a Nurses 96
Wong [22] 1987 RCT USA Mixed Community 79.00
(66-90)
Sealed.^ 31 non-consecutive-
dose foil-backed
compartments. Each card
serves one daily time point
for one month e.g. breakfast.
Standard
packaging
(bottles)
Pharmacy
or
researcher
17
Unsealed=resealable/reuseable rigid plastic with sliding or flip-top lids usually filled by patient; Sealed=heat or cold sealed with foil or paper, usually filled in
pharmacy; n/a = not applicable; nr = not reported or insufficient detail; * Audit of 2480 patients’ Webster-paks™ at aged care facilities in New South Wales( 6972
packs were audited); Ɨ Study explored errors reported in the Australian Incident Monitoring Study, with analysis based on the 52 incidents involving MODs. ^ 31
compartments per card marked with days of the month. Only one compartment per day. Card marked with e.g. breakfast or dinner. A number of cards needed
per patient on any one day
Table 2 Risk of bias for included studies
Items from Cochrane risk of bias tool
Study Study design Randomisation
procedure
Concealment
of allocation
Blinding of
assessors
Blinding of treatment
providers
Attrition
addressed
All outcomes
reported
Other risks
of bias
Becker [20] RCT ? ? ? x ? ? x
Carruthers [32] Audit NA NA NA NA NA ? ✓
Crome [27] RCT ? ? ? ? ✓ ? ✓
Feetam [21] Prospective NA NA NA NA NA ? ✓
Huang [23] RCT ✓ ✓ ? ? ? ? ✓
Levings [33] Audit NA NA NA NA NA ? x
MacIntosh [28] RCT ✓ ? ? ? ✓ ? ✓
McElnay [19] Cross-section NA NA NA NA NA x x
Petersen [24] Prospective ? ? ? ? ✓ ? ✓
Rehder [25] RCT ? ? ? ? ? ? ✓
Roberts [18] Cross-section, audit NA NA NA NA NA ? x
Ryan-Woolley [29] RCT ? ? ? ? ✓ ? ✓
Simmons [26] RCT ✓ ? ? x ✓ ? ✓
Skaer [31] RCT ? ? ? ? ? ? ✓
Skaer [30] RCT ? ? ? ? ? ? ✓
Stewart [34] Cross-section NA NA NA NA NA ? ✓
Wong [22] RCT ? ? ? ? x ? x
✓ reported/low risk of bias, x not reported/high risk of bias, NA not applicable, ? unclear
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Healthcare utilisation
Only three studies [18, 29, 30] examined the effects of
MODs on healthcare utilisation. In all three studies the
MODs were filled at the pharmacy. No consistent find-
ings were identified; a significant reduction in non-
emergency access to healthcare was reported by Roberts
et al. [18] in a cross-sectional study. However, non-
significant reductions in costs of non-emergency access
to physicians (-$19.51) and hospital expenditure
(-$22.91) were reported in an RCT by Skaer et al. [30]
and a small, significant increase in healthcare utilisation
was observed in an RCT by Ryan-Woolley et al. [29].
The effects of MODs on healthcare utilisation are
provided in Table 5. Estimates of MOD impact on pre-
scribing costs were provided in two RCT studies with
conflicting findings [29, 30]. Skaer et al. using
Table 4 Effect of MODs on medication adherence
Study Design Adherence measure n MOD n Control Adherence MOD Adherence control p-value
Becker 1986 [20] RCT % participants taking > 80 % of doses 86 85 84 75.3 > 0.05
Crome 1982 [27] RCT % doses missed 40 38 26.1 26.2 > 0.05
Huang 2000a [23] RCT % participants > 90 % of doses 90 94 91 94 Not stated
Median % of doses taken 94 100 99 0.63
Huang 2000b [23] RCT % participants taking > 90 % of doses 148 149 87 93 0.005*
Median % of doses taken 99 99 > 0.05
MacIntosh 2007 [28] RCT % participants taking 100 % of doses 21 21 81 86 Not stated
Petersen 2007 [24] Prospective Increase in % doses taken 4.1 % - < 0.05*
Rehder 1980 [25] RCT % participants taking > 95 % of doses 25 25 89 47 < 0.01*
Wong 1987 [22] RCT % doses missed 17 17 2.04 9.17 < 0.01*
*indicates a significance level of p < 0.05
n Mod indicates the number of participants in the group utilizing a MOD
n control indicates the number of participants in the group not utilizing a MOD
Table 3 Impact of MODs on health outcome
Study Design Outcome measure Change in outcome n MOD n control p-value
Becker 1986 [20] RCT Diastolic blood pressure β = 1.45 86 85 0.259
Huang 2000a [23] RCT Change in Vitamin C serum
concentration
-0.9 (mg/dl) 90 94 0.47
Change in Vitamin E serum
concentration
-2.4 (mg/dl) 0.06*
Huang 2000b [23] RCT Change in Vitamin E serum
concentration
0.9 (mg/dl) 148 149 0.53
Petersen 2007 [24] Prospective Viral Load 0.36 mean log10 copies/mL. Increased
odds of viral load below 400 copies/ml
OR 1.91
<0.05*
Rehder 1980 [25] RCT Change in diastolic blood pressure 1 mm Hg 25 25 > 0.05
Change in systolic blood pressure Not reported > 0.05
Roberts 2004 [18] Cross-section Number of adverse drug reactions
(ADRs)
Non-MOD group reported more ADRs
(47.79 %) vs non-pharmacist filled MOD
group (43.24 %) and pharmacist filled
MOD group (32.56 %)
0.022*
The 14 item Older Americans Resource
Scale for Instrumental Activities of Daily
Living (OARS-IADL)
Pharmacist filled MOD group had lower
ability scores (10.25) vs non-pharmacist
filled MOD group (12.70) and non-MOD
group (12.34)
0.001*
Simmons 2000 [26] RCT Change in diastolic blood pressure -5.9 mm Hg 36 32 0.0041*
Change in systolic blood pressure -1.0 mm Hg 0.89
Change in HbA1c -0.8 % 0.026*
*indicates a significance level of p < 0.05
n Mod indicates the number of participants in the group utilizing a MOD
n control indicates the number of participants in the group not utilizing a MOD
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medication possession ratios, reported a significant in-
crease in mean prescription expenditure of $74.09 for
patients with diabetes [30] and $48.17 for patients with
hypertension [31]. In both cases these extra costs ne-
gated savings reported in hospital and non-emergency
healthcare access to generate a non-significant overall
increase in healthcare costs for patients with MODs
compared to controls. Ryan-Woolley et al. reported a
significant reduction in the number of prescribed
medicines.
Dispensing errors
Three studies investigated the frequency of dispensing
errors [18, 32, 33]; there was little consistency in find-
ings. All studies discussed the error rate with MODs
without reference to any comparison. The study by
Carruthers et al, [32] described a nurse conducted audit
of the accuracy of filling MODs by nurses. The study in-
cluded 2480 residents in 42 regional aged care facilities.
Errors were identified in 4.3 % (297/6972) of MODs in-
volving 12 % of the residents. The different sources of
error are displayed in Table 6. In a smaller study, [18]
190 direct observations by researchers of MODs being
filled by pharmacist, dispensary assistant, or pre-
registration pharmacy student reported an error rate of
44.7 % of MODs. This compared to only 5.7 % when re-
ported by staff. It was suggested that when observed,
the persons filling the MODs made more errors and
that the researcher had a more stringent definition of
an error. The error types are also displayed in Table 6.
Higher error rates were associated with larger facilities
(χ2 = 6.374, p = 0.042), longer duration of time spent
filling (r = 0.342, p = 0.004), and interruptions (r = -
0.337, p = 0.003).
Finally an audit by Levings et al. [33] (Australian
Incident Monitoring Study) examined the first 12,000
generic incident reports. Reports involving MODs
accounted for 0.43 % of all errors (54/12,000) and de-
scribed 54 separate MOD-related incidents. Of these 54
incidents, 26 (48 %) were either actual (16) or potential
(10) errors associated with filling MODs, 16 (29.6 %)
were patient errors and 12 (eight actual and four poten-
tial) were associated with inappropriate concomitant
use of drugs.
Supply procedures and costs
Four studies estimated the time taken to fill MODs
[18, 19, 21, 34]. In a simulated study involving five
pharmacists and a pharmacy technician using medi-
cines for five fictitious patients, McElnay and Thomp-
son [19] compared the time taken to fill six different
MODs and the perceived ease of filling (Table 7).
Pharmacist-ranked ‘ease of filling’ largely matched the
ranking for fill time. Even for the MOD which was the
quickest to fill, it was estimated that it would take on
average seven minutes per patient per month longer
than for standard packaging. This estimate was for
MODs filled from pre-prepared bottles of medication
already removed from the manufacturer’s packaging,
and based on multiplying the 105 s taken to fill the
(DossetTM) MOD by four (weeks). The study was re-
ported in 1992. At that time manufacturers supplied
medicines in bottles or tubs whereas current practice
is primarily blister packs. In order to dispense into
Table 5 Impact of MODs on healthcare utilisation
Study Design n
MOD
n
Control
Healthcare Utilisation Measure Healthcare Utilisation MOD Healthcare
Utilisation Control
p-value
Roberts 2004
[18]
Cross-
section
209 144 Mean no. consultations with a
different prescriber
2.02 (pharmacist supplied) 2.41 0.012*
2.91 (non-pharmacist supplied)
Mean no. prescriber consultations
in previous two months
2.54 (pharmacist supplied) 3.05 0.03*
2.05 (non-pharmacist supplied)
Mean no. hospital admissions in
previous 12 months
1.36 (pharmacist supplied) 0.78 0.001*
0.56 (non-pharmacist supplied)
% patients hospitalised in previous
three months
59.54 % (pharmacist supplied) 35.14 %
35.14 % non-pharmacist supplied)
Ryan-Woolley
2005 [29]
RCT 31 31 Mean no. prescriber consultations 1.5 1.3 0.07
Mean no. prescribed medicines 4.2 4.8 0 .024*
Skaer 1993 [31] RCT 85 78 Mean healthcare spending (Medicaid
archive data)
$13.66 per patient increase
compared to control group
> 0.05
Skaer 1993 [30] RCT 53 78 Mean healthcare spending (Medicaid
archive data)
$22.94 per patient increase
compared to control group
> 0.05
*indicates a significance level of p < 0.05
n Mod indicates the number of participants in the group utilizing a MOD
n control indicates the number of participants in the group not utilizing a MOD
Watson et al. BMC Health Services Research  (2016) 16:202 Page 9 of 13
MODs, transfer of medication is generally therefore
from blister packs rather than bottles which adds to
the fill-times estimated in 1992. Furthermore, there
was no consideration of the time resource required for
labelling.
Roberts [18] using direct observation and audit of log
books, identified that the time required to fill a MOD
ranged from 3.2 to 8.6 min for large packing operations
(supplying 351 – 5000 patients per week) and 14 to
18.5 min for small packing operations (supplying less
than 90 patients per week). Time spent checking MODs
ranged from 1.13 to 2.13 min for large operations to
3.01 to 8.61 min for small operations. Those filled using
automated packing systems took less time to pack
(0.99 min) while blister packs (3.34 min) and Dosset™
boxes (10 min) took longer.
Feetam and Kelly [21] found that a Medidos™ MOD
took an average of three minutes to fill and 24 min to
label in a prospective study.
In a survey of 153 Scottish community nurses, 96
(63 %) reported experience of filling MODs [34]. The es-
timated average time for a nurse to fill one MOD was
34.2 min. The survey also identified concerns regarding
the impact of this workload on nurse schedules, lack of
any formal training (most had received no training, 25 %
had received informal training) and lack of knowledge
about which medicines could be placed in MODs.
Nearly 60 % of the nurses felt that pharmacists should
fill the MODs.
Two studies examined the costs of using MODs [18,
21]. Feetam and Kelly [21] estimated the cost of supply-
ing MedidosTM MODs for six months to be 0.1 GBP per
week compared to 0.21 GBP per week for seven dispos-
able bottles. Similarly labelling was less expensive (0.01
GBP versus 0.04 GBP), as was time spent labelling and
filling (0.16 GBP versus 0.24 GBP). Overall this pro-
duced an estimated cost of 0.27 GBP per week for a
Medidos™ containing seven medicines per day versus
seven pill bottles costing 0.49 GBP per week. Roberts
[32], however, reported the cost of providing medication
in standard medication packaging (usual care) relative to
a MOD. The cost of original packaging per year
($942.73) was less than using a MOD ($1859.00 per
year).
Discussion
This systematic review identified 17 studies examining
the effect(s) of MODs on health outcomes or supply
processes. Unlike previous reviews, this study intended
to isolate the effects of MODs in the absence of re-
minder devices, calendars or other memory aids. Overall
study quality was poor, both in terms of research design
and execution. Heterogeneity in types of patient, type of
MOD and reported outcomes precluded a meta-analysis.
Table 7 Summary of MOD filling experience [19]
MOD Time taken Perceived ease
(minutes:
seconds)
(1 - favourable
to10 - unfavourable)
Dosset 1:45 8.3
Pill Mill 2:27 5
Round tray 4 compartments
7 days
Medsystem Week Pouch 2:48 7.7
Daily boxes with four
compartments in a pouch
Medidos 2:52 7.8
Stacked wheels 4 compartments
7 days
Medi-Wheel 3:20 7.5
Stacked wheels 4 compartments
7 days
Supercel 9:59 1.5
Seven by four pouches on a
card
Table 6 Summary of the types of errors identified
Study Design Error Type Error rate
Carruthers
2008 [32]
RCT Omission of a medicine 99/297 (33.3 %)
Supplying a medicine
discontinued by the
general practitioner
37/297 (12.5 %)
Wrong strength 32/297 (10.8 %)
Incorrect instructions 32/297 (10.8 %)
Failure to deliver
medicines
13/297 (4.4 %)
Wrong medicine 12.297 (4.0 %)
Wrong label 7/297 (2.4 %)
Other/Unknown 65/297 (21.9 %)
General practitioner error 79/297 (26.6 %)
Pharmacy error 125/297 (42.1 %)
Not attributable 93/297 (31.3 %)
Roberts
2004 [18]
Cross-section,
audit
Missing tablets 75/190 (39.5 %)
Extra tablets 46/190 (24.2 %)
Tablet in wrong position 23/190 (12.1 %)
Medication changes not
made
17/190 (8.9 %)
Labels incorrect 9/190 (4.7 %)
Wrong tablet 7/190 (3.7 %)
Pack/sachet/drug damaged 6/190 (3.2 %)
Special medications not
packed correctly/packed
when should not be
4/190 (2.1 %)
Authority script required 2/190 (1.1 %)
Wrong colour card 1/190 (0.5 %)
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Overall evidence for efficacy of MODs was mixed; whilst
there was some suggestion of benefit such as improved ad-
herence, or reduced service utilisation this was not reflected
in all studies. This uncertainty regarding MOD effects on
pill count measured adherence is not reflected in the review
conducted by Mahtani et al.; this reported a pooled effect of
significantly greater adherence with MODs relative to con-
trol [10]. There are two potential explanations for this dif-
ference in outcome. The first is that Mahtani et al. use a
wider definition of “pill count” than the present review by
including studies such as Skaer et al. [31] that measured ad-
herence using prescription refills. This is an imprecise
measure of adherence as it is significantly removed from
the act of taking medication taking [35]. The second is that
their conclusions are primarily based on their meta-analysis
which demonstrated a high level of heterogeneity. The re-
sults should therefore be interpreted with caution as esti-
mates can be as much the consequence of differences
between studies as any effect of the intervention. The
present study identified similarly high levels of heterogen-
eity thus a narrative review was deemed more appropriate.
One reason for a lack of efficacy could be that MODs were
not always targeted at patients with an identified need, and
in those studies in which patients were targeted, greater
benefit was observed [18, 24]. Ideally a study seeking to ap-
praise MODs should select patients demonstrating uninten-
tional non-adherence. Even then MODs represent only one
of many potential strategies that could help to reduce non-
adherence by facilitating habit-forming strategies [36–38].
Previous reviews have drawn similar conclusions such as
Mahatani et al. [10] who state that “there is no single inter-
vention strategy which has been shown to be effective across
all patients, conditions and settings”. Unlike the present
study, they do not offer any indication of the circumstances
that aremore likely to be associated withMODbenefits.
Pill count was used to estimate adherence in the interven-
tion group for all studies. Pill count is a pragmatic and
widely accepted approach to adherence assessment [3, 17]
and despite its limitations regarded as the gold standard
when electronic monitoring is not possible [17]. Whilst it is
objective, it is based on the assumption that if the medica-
tion is not in the container it has been taken by the patient.
This is a limitation because patients may deliberately re-
move and discard tablets in order to disguise non-
adherence when under observation [7]. Thus the assump-
tion is only valid if patients are predominantly unintention-
ally non-adherent. However, in the identified studies,
participant non-adherence type was not identified thus
there is a risk of overestimating adherence [39]. Pill counts
also fail to identify patterns of non-adherence; occasional
missed doses and longer breaks from taking medication are
not distinguished as only the absolute number of medicines
taken is estimated [17, 40]. Such limitations of reporting are
not considered by previous reviews [10–13, 41].
Evidence for the utility of MODs in reducing the need
for healthcare services such as physician visits or hospi-
talisation was also mixed. One study found that MODs
initiated by pharmacists reduced the number of commu-
nity physician visits but hospitalisations increased [18].
A second study reported increased community physician
visits but a reduction in the number of medications pre-
scribed [29]. It is difficult to attribute causality in these
cases. In Ryan-Wooley and Rees [29] the difference is
small and potentially due to chance, while in the study
reported by Roberts [18] patients initiated on a MOD by
a pharmacist scored lower than comparison groups in
terms of functional ability and so may have been less
able to complete day to day activities. However, and
more fundamentally, the cross-sectional nature of Rob-
erts [18] makes causal assumptions especially difficult.
Whilst the evidence is far from unequivocal, these two
studies do suggest the possibility that MODs increase
the need for healthcare utilisation, for example by in-
creasing the risk of adverse drug reactions [41]. It is im-
portant that further research be conducted to explore
the possibility of this potential hazard [42].
A second cause for concern was the potential for
MODs to introduce dispensing errors into patients’
medication regimens. Again evidence is scant; two stud-
ies found reported error rates of around 4-6 % [18, 32],
but independent researcher checking identified a much
higher error rate of over 40 % [18]. There is a clear need
to identify both the rate and severity of errors associated
with the use of MODs. The error rate may also differ de-
pending on who is filling the MOD; it was notable that
one study found that community nurses asked to fill
MODs considered themselves unqualified for this task
which adversely affected their working schedules [34].
Thus there could be benefit in identifying the most ap-
propriate way to fill MODs that minimises potentially
harmful errors while optimising the use of healthcare
professionals’ time. Similarly, the economic costs and
benefits of staff filling MODs are currently unknown.
Only two studies have explored the costs of supplying
MODs and provide conflicting evidence for the overall
cost effectiveness of doing so [18, 21].
The systematic review methodology adopted followed
standard best practice. However, as with all searches it is
possible that some papers were missed either through
the search process, or because only papers written in
English were included. Only eight of the papers reported
work conducted since 2000, and the relevance of the
older papers may therefore also be queried because of
changing contexts, increased understanding of adher-
ence and methodological best practice. Boeni et al. re-
ported a similar observation, noting that reporting
quality improved significantly in studies published after
the CONSORT statements were published [13].
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Conclusions
There is a dearth of evidence for the use of MODs.
There is potential for MODs to improve patient health
outcomes and adherence to medication, but this benefit
may come with an increased risk of additional healthcare
intervention from a general practitioner or even hospi-
talisation. Currently the evidence base is not available to
properly appraise these potential risks or benefits, and
given the wide usage of MODs the potential for harm
should be a significant cause for concern. There is also a
wider need for more thorough appraisal of the economic
benefits or otherwise of MODs, including comparing
them to other interventions which seek to alleviate unin-
tentional non-adherence. These studies are necessary be-
fore MODs can be used optimally.
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